hotspot -WSS

hotspot

author：entertainment 2025-09-06 03:57:08 - browse：5

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The Food and Drug Administration on Thursday approved an Eli Lilly drug that takes a new approach to treating ulcerative colitis, a chronic inflammatory disease that can cause intense gastrointestinal pain and distress.

The therapy, dubbed Omvoh, is an antibody that blocks IL-23p19, an immune signaling molecule that plays a key role in sustaining the disease. It’s the first treatment to target this particular pathway in ulcerative colitis. The drug’s approval comes after two late-stage trials found that patients taking Omvoh showed a significant improvement in symptoms after both three months and a year compared with those given a placebo, and that the therapy had minimal side effects.

Omvoh’s list price will be $9,593 per month for intravenous delivery and $10,360 per dose injected beneath the skin. A company spokesperson told STAT that patients who have the drug covered by commercial insurance may pay as little as $5 per month for up to 30 months.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： H5N1 virus can be tracked in retail milk, scientists say

hotspot

WSS

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

H5N1 virus can be tracked in retail milk, scientists say

H5N1 bird flu outbreak: Second human case reported, in Michigan

Liver decline slowed by off

Study suggests Covid rebound is far more common with Paxlovid than without

After decades in use, heart stents finally beat placebo

Wikipedia

hotspot

hotspot

Activists slam private health insurers over coverage restrictions

Digital health: a case of mistaken identity

Sports medicine is finally prioritizing gender equality

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Trump demands the U.S. pay no more for drugs than other countries … again

Addressing health care workers' trauma can help fight burnout

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

What is STAT's opinion section for?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Cue Health, Covid

hotspot

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Ventyx halts psoriasis drug development after lackluster trial results

Bird flu surveillance in wastewater gets boost from consortium

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Cue Health, Covid

Weight loss drugs should be covered by insurers, AMA says

leisure time

hotspot

entertainment

leisure time